Last reviewed · How we verify
Perindopril tert-Butylamine tablets(ACERTIL®) — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Perindopril tert-Butylamine tablets(ACERTIL®) (Perindopril tert-Butylamine tablets(ACERTIL®)) — Sichuan Haisco Pharmaceutical Group Co., Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Perindopril tert-Butylamine tablets(ACERTIL®) TARGET | Perindopril tert-Butylamine tablets(ACERTIL®) | Sichuan Haisco Pharmaceutical Group Co., Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Perindopril tert-Butylamine tablets(ACERTIL®) CI watch — RSS
- Perindopril tert-Butylamine tablets(ACERTIL®) CI watch — Atom
- Perindopril tert-Butylamine tablets(ACERTIL®) CI watch — JSON
- Perindopril tert-Butylamine tablets(ACERTIL®) alone — RSS
Cite this brief
Drug Landscape (2026). Perindopril tert-Butylamine tablets(ACERTIL®) — Competitive Intelligence Brief. https://druglandscape.com/ci/perindopril-tert-butylamine-tablets-acertil. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab